BioCentury
ARTICLE | Company News

FDA accepts suvorexant NDA

November 9, 2012 1:41 AM UTC

Merck & Co. Inc. (NYSE:MRK) said FDA accepted for review an NDA for suvorexant to treat insomnia. The pharma would not disclose a specific PDUFA date or when the application was submitted. In its 10-Q...